Evidence map›Paper›PMID 42133170›Full record

ReviewApplied biochemistry and biotechnology2026

Decoding the Genetic Hallmarks of Breast Cancer: Molecular Signatures, Prognostic and Therapeutic Perspectives.

Sahasra Allu, Yalini Saravanan, Kunnathur Murugesan Sakthivel, Kathirvelan Chinnadurai, Pavithra Kumar, Mythili Saravanan, Rajan Radha Rasmi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sahasra AlluApex Research and Scientific Writing Academy, Cary, Durham, NC, 27707, USA.
Yalini SaravananApex Research and Scientific Writing Academy, Cary, Durham, NC, 27707, USA.
Kunnathur Murugesan SakthivelDepartment of Biochemistry, PSG College of Arts and Science, Civil Aerodrome Post, Coimbatore, Tamil Nadu, 641014, India.
Kathirvelan ChinnaduraiDepartment of Animal Nutrition, Veterinary College and Research Institute, TANUVAS, Udumalpet, Tamil Nadu, 642205, India.
Pavithra KumarDepartment of Biochemistry, PSG College of Arts and Science, Civil Aerodrome Post, Coimbatore, Tamil Nadu, 641014, India.
Mythili SaravananDepartment of Pharmaceutical Sciences, Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC, 27707, USA.
Rajan Radha RasmiDepartment of Biotechnology, PSG College of Arts and Science, Civil Aerodrome Post, Coimbatore, Tamil Nadu, 641014, India. rashmiffrajan@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is prevalent among millions of women worldwide and is considered one of the leading causes of cancer mortality in women. Genetic factors play a significant role in the pathogenesis and treatment options for breast cancer. Multiple genes such as BRCA1, BRCA2, CHEK2, ATM, HER2 and PALB2 play crucial roles in breast cancer development. The mechanism of action and their interaction with other genes in response to DNA damage impacts the development of cancer. The mechanism of regulation of each gene is also central when developing drug therapies targeted towards the genetic influences of breast cancer. Current FDA approved drugs and drugs in clinical trials targeted toward the genetic influences of breast cancer include those such as Talazoparib and Margetuximab. Additionally, risk assessment and genetic screening methods are incredibly important to inform patients of their individual risk for breast cancer development. Advancements in understanding of gene specific mechanism and their correlation with breast cancer pathogenesis may provide efficient strategies for precision medicine and enhancing clinical outcomes in breast cancer patients.

Indexed as

Breast NeoplasmsBiomarkers, TumorFemaleHumansPrognosisBiomarkers, TumorBiomarkersBreast cancerDiagnosisGenetic factorsTherapeutic targets

Identifiers

PMID42133170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.